Skip to main content
Signal8

Dogwood Therapeutics Announces Third Quarter 2026 Financial Results

$DWTXPress releaseNov 5, 2026, 8:30 AM ET

Dogwood Therapeutics reported Q3 2026 net loss of $4.9 million ($0.14 per share), with $0.1 million in first-ever licensing revenue from the PRIDCor agreement. The Halneuron Phase 2b trial in chemotherapy-induced neuropathic pain is fully enrolled with 239 patients, and top-line results are expected this November — the company's key near-term catalyst. Dogwood closed a $5 million private placement with its largest shareholder Sealbond Limited (a CK Life Sciences subsidiary); combined with $4.9 million of cash, runway extends only through Q1 2027.

Key figures

Revenue
100000
Runway
through Q1 2027
Net loss
4882942
Cash on hand
4948266
Lte patients
95
Ga expense q3
1576219
Rd expense q3
3352977
Phase2b cinp patients
239
Private placement usd
5000000

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.